Currently, there are 84.49M common shares owned by the public and among those 84.49M shares have been available to trade.
The company’s stock has a 5-day price change of -19.41% and -51.54% over the past three months. TNXP shares are trading -62.80% year to date (YTD), with the 12-month market performance down to -95.33% lower. It has a 12-month low price of $0.14 and touched a high of $3.34 over the same period. TNXP has an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -38.43%, -51.48%, and -76.82% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares accounts for 19.87% of the company’s 84.49M shares outstanding.
It has a market capitalization of $12.67M and a beta (3y monthly) value of 2.23. The earnings-per-share (ttm) stands at -$8.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.87% over the week and 15.36% over the month.
Analysts forecast that Tonix Pharmaceuticals Holding Corp (TNXP) will achieve an EPS of $Tsakos Energy Navigation Ltd for the current quarter, $25.32 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Nuveen Select Tax Free Income P while analysts give the company a high EPS estimate of $UNITED EXPRESS INC. Comparatively, EPS for the current quarter was $PINEAPPLE EXPRESS CANNABIS CO a year ago. Earnings per share for the fiscal year are expected to decrease by -102.91%, and 30.95% over the next financial year.
ROTH Capital coverage for the Tonix Pharmaceuticals Holding Corp (TNXP) stock in a research note released on April 18, 2019 offered a Buy rating with a price target of $4. Oppenheimer on their part issued Outperform rating on February 17, 2016.
